Core Viewpoint - Senseonics Holdings, Inc. has initiated an underwritten public offering of its common stock, with a potential additional 15% of shares available for underwriters to purchase [1][2]. Group 1: Offering Details - The public offering is subject to market conditions and will be made under a "shelf" registration statement filed with the SEC [3]. - TD Cowen and Barclays are the joint book-running managers for the offering, with RBC Capital Markets and Lake Street acting as bookrunners [2]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on their website [3]. Group 2: Concurrent Private Placement - Abbott Laboratories has agreed to purchase up to $25 million of Senseonics' common stock in a separate private placement, contingent on the public offering's closing [4]. - The net proceeds from both the public offering and the concurrent private placement will be used to support the launch of Eversense 365, ongoing product development, and general corporate purposes [5]. Group 3: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management, with products like Eversense® 365 and Eversense® E3 [8]. - The company's CGM systems feature a small sensor that is implanted under the skin and communicates glucose data to a mobile app every 5 minutes [8].

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIEWBIX INC. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on May 14, 2025 Registration No. 333-281143 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 3 Hanehoshet St, Building B, 7th floor Tel Aviv, Israel 6971068 +972-9774-1505 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code ...

Core Viewpoint - Southern Cross Gold Consolidated Ltd has successfully closed the second tranche of its private placement, raising approximately C$29.87 million to support the development of the Sunday Creek Gold-Antimony Project in Australia [1][4]. Group 1: Financial Details - The second tranche involved the issuance of 6,636,918 common shares, with 550,000 converted to Chess Depositary Interests (CDIs), at a price of C$4.50 (A$5.10) each [2][10]. - The total gross proceeds from the second tranche amounted to C$29,866,131 [2][7]. - A third tranche is anticipated to close around May 16, 2025, with expected gross proceeds of up to approximately C$24.44 million [4]. Group 2: Project Development - The net proceeds from the placement are earmarked for key milestones in the Sunday Creek project, including C$53 million for drilling to establish an Inferred Resource by Q1 2027, C$27 million for decline development, C$4 million for a Preliminary Economic Assessment, and C$59 million for exploration and working capital [11]. - The Sunday Creek project is located 60 km north of Melbourne and is recognized as one of the significant gold and antimony discoveries in the Western world, with a mineralization structure extending over 12 km [13][14]. Group 3: Strategic Importance - The dual-metal profile of the Sunday Creek project, with antimony contributing 20% of the in-situ value alongside gold, positions the company strategically, especially in light of China's export restrictions on antimony [14]. - Southern Cross Gold's inclusion in the US Defense Industrial Base Consortium and legislative changes related to AUKUS enhance its potential as a key supplier of antimony in the West [14].

Core Viewpoint - Altura Energy Corp. is conducting a private placement offering of up to 15,000,000 units at a price of $0.10 per unit, aiming for gross proceeds of up to $1,500,000 [1][5] Group 1: Offering Details - Each unit consists of one common share and one warrant, with the warrant allowing the purchase of one common share at an exercise price of $0.25 for up to sixty months [2] - The company has granted the agent an option to sell an additional 2,250,000 units for up to $225,000 in gross proceeds [3] - The offering will be conducted as a private placement under applicable exemptions from prospectus requirements in Canada and other mutually agreed jurisdictions, excluding the United States [4] Group 2: Closing and Use of Proceeds - The offering is expected to close around June 4, 2025, subject to necessary approvals, including from the TSX Venture Exchange [5] - Net proceeds from the offering will be used to repay existing debt and for working capital and general corporate purposes [6] Group 3: Company Background - Altura Energy Corp. is an exploration and production company with interests in the Holbrook basin of Arizona [8]

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Carlton Precious Inc. (TSX-V: CPI | OTCQB: NBRFF) (“Carlton” or the “Company”) announces that it will undertake a non-brokered private placement to raise up to $1,035,000 through the issuance of up to 11,500,000 units (the “Private Placement”), each Unit being priced at $0.09 and comprising one common share and one-half common share purchase warrant (each whole warrant, ...

Core Viewpoint - MetaVia Inc. has announced a private placement expected to generate approximately $10.0 million in gross proceeds, aimed at supporting the clinical development of its obesity treatment, DA-1726 [1][2]. Group 1: Private Placement Details - The offering includes the purchase of 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded warrants at $0.709 each, with an exercise price of $0.001 [2]. - The private placement is priced at-the-market under Nasdaq rules, with the closing expected around May 12, 2025, subject to customary conditions [2]. Group 2: Regulatory and Compliance Information - The securities are being offered to certain institutional accredited investors and are not registered under the Securities Act, thus cannot be sold in the U.S. without an effective registration statement or applicable exemption [3]. - MetaVia plans to file a registration statement with the SEC for the resale of the shares issued in the private placement and to obtain stockholder approval for the underlying shares of the pre-funded warrants [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [5]. - DA-1726 is a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, potentially leading to superior weight loss compared to selective GLP1R agonists [5]. - DA-1241 is a GPR119 agonist that promotes the release of gut peptides and has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [5].

Core Points - AlphaGen Intelligence Corp. announced a non-brokered private placement offering of up to 2,437,500 units at a price of $0.08 per unit, aiming for gross proceeds of up to $195,000 [1][3] - Each unit consists of one common share and one whole share purchase warrant, with the warrant convertible into an additional share at an exercise price of $0.12 for two years [2] - The net proceeds from the offering will be used for general working capital purposes, and the offering is expected to close around May 16, 2025, pending regulatory approvals [3] Company Overview - AlphaGen Intelligence Corp. is publicly traded and holds a portfolio in gaming, entertainment, eCommerce, and retail [5] - The company operates units such as Shape Immersive, a metaverse studio, and MANA, a SaaS solution for community engagement [5] - Notable clients and partners include RTFKT, Olympics, Red Bull, Intel, and TED [5]

Company Overview - Dogness (International) Corporation is a developer and manufacturer of a comprehensive line of Dogness-branded, OEM, and private label pet products [1] - The company was founded in 2003 with a focus on enhancing the relationship between pets and their caregivers through smart products, hygiene products, health and wellness products, and leash products [4] - Dogness has over 200 patents and patents pending, ensuring industry-leading quality through a fully integrated vertical supply chain and world-class research and development capabilities [4] Private Placement Details - Dogness announced a private placement transaction for US$6.0 million in gross proceeds from the sale of 1,200,000 Class A common shares at US$5.00 per share [1] - The shares are being sold to certain non-U.S. purchasers in a transaction exempt from registration under the Securities Act of 1933, relying on Regulation S [2] - Closing of the private placement is subject to customary closing conditions [2]

Company Overview - Southern Cross Gold Consolidated Ltd (TSXV: SXGC) (ASX: SX2) has successfully closed the first tranche of its private placement, raising C$88,799,220 through the issuance of 19,733,160 common shares and Chess Depositary Interests (CDIs) at a price of C$4.50 (A$5.10) per share [1][2][4] Placement Details - The first tranche of the placement involved the issuance of 16,171,050 CDIs and 3,562,110 common shares, with gross proceeds of A$82,472,355 and C$16,029,495 respectively [5][8] - A second tranche is anticipated to close around May 14, 2025, aiming for additional gross proceeds of approximately C$54,308,502 [4] Use of Proceeds - The net proceeds from the placement are earmarked for key milestones in the development of the Sunday Creek Gold-Antimony Project, including: - C$53 million for drilling to establish an Inferred Resource by Q1 2027 - C$27 million for decline development to enhance access to mineralization - C$4 million for a Preliminary Economic Assessment - C$59 million for exploration target expansion and working capital over three years [9] Project Significance - The Sunday Creek project, located 60 km north of Melbourne, Australia, is recognized as a significant gold and antimony discovery, with a mineralization structure extending over 12 km [13][14] - The dual-metal profile of the project, with antimony contributing 20% of the in-situ value, positions it strategically in light of China's export restrictions on antimony, a critical metal for defense and semiconductor applications [14] Insider Participation - Mr. Darren Morcombe, an insider of the company, subscribed for 980,392 CDIs under the first tranche, increasing his total holdings to 28,991,112 common shares, representing approximately 11.91% of the outstanding shares [11][12]

Core Viewpoint - Abcourt Mines Inc. has successfully closed an additional tranche of its non-brokered private placement, raising a total of $9,281,044 to support the restart of the Sleeping Giant mine and for general corporate purposes [1][4]. Group 1: Private Placement Details - The recent tranche raised gross proceeds of $4,613,004, contributing to a total of $9,281,044 raised through private placements [1]. - The private placement consists of units priced at $0.05 each, with each unit comprising one common share and one warrant [2][9]. - Each warrant allows the holder to purchase one common share at a price of $0.08 for a period of 36 months following the closing date [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized to restart the Sleeping Giant mine and mill, along with working capital and general corporate purposes [4]. Group 3: Related Party Transactions - The private placement involved related party transactions, with insiders purchasing a total of 20,000,000 units [5][11]. - The Corporation relied on exemptions from formal valuation and minority shareholder approval requirements due to the transaction's value being below 25% of the Corporation's market capitalization [5]. Group 4: Securities and Regulatory Compliance - All securities issued in connection with the private placement are subject to a restricted period of four months plus one day from the issuance date [6]. - The private placement remains subject to final approval from the TSX Venture Exchange [10].